Respiratory Plus: Cipla Shapes Future In New Age Platforms, Devices, Diagnostics

The next chapter of Cipla’s innovation journey goes beyond its core respiratory thrust to include new platforms spanning areas such as peptides, where it has seen its first major approval in the US and has multiple programs lined up. Devices and diagnostics are among the other avenues being explored as the Indian company seeks to bring more patients into the “funnel”.

Cipla Limited is eyeing a much wider canvas of opportunities beyond its lung leadership ambitions and expects to extend its innovation engine to “new-age” platforms, devices and diagnostics, some of these aligned with its core strength in the respiratory segment.

Addressing the annual J.P. Morgan Healthcare Conference, the Indian company’s global CEO and managing director, Umang Vohra, indicated that while...